BUNAVAIL (buprenorphine and naloxone) buccal film is a citrus flavored oral transmucosal form of buprenorphine, an opioid partial agonist, and naloxone, an opioid antagonist, intended for application to the buccal mucosa.
CASSIPA film contains buprenorphine, a partial‐opioid agonist, and naloxone, an opioid antagonist, and is indicated for the maintenance treatment of opioid dependence.
Learn about EVZIO® (naloxone HCl injection), the first and only naloxone auto-injector approved by the FDA.
ZUBSOLV® (buprenorphine and naloxone) is indicated for the treatment of opioid dependence. This site is designed for healthcare professionals.
Aug 5th, 2019 - The overdose-reversing drug naloxone saves lives – but only if it’s readily available when an overdose occurs. Despite a huge increase in naloxone prescribing in recent years, CDC researchers report in the latest Vital Signs study published today that far too little naloxone is being dispensed in many areas of the country that need it the most.
Information for prescribers about the organizations and Surgeon General advice to co-prescribe naloxone to patients who will have opioids. Also includes the Surgeon General’s speech on opioids and co-prescribing naloxone.
Aug 5th, 2019 - About 48,000 US drug overdose deaths involved opioids in 2017. Naloxone is a life-saving medication that can reverse the effects of an opioid overdose. Pharmacists and other healthcare providers play a critical role in ensuring patients receive naloxone.
American Society of Addiction Medicine
Oct 7th, 2016 - Naloxone is a mu-opioid antagonist with well-established safety and efficacy that can reverse opioid overdose and prevent fatalities. Naloxone treatment of opioid overdose has been in use in hospital settings for decades.
U.S. Department of Health and Human Services (HSS)
Dec 18th, 2018 - The Centers for Disease Control and Prevention (CDC) reports that 70,237 Americans died from drug overdoses in 2017, of which 47,600 were opioid related. Also in 2017, 11.
TARGINIQ ER is a combination product consisting of oxycodone, an opioid agonist, and naloxone, an opioid antagonist, indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Aug 19th, 2019 - Naloxone only lasts between 30 – 90 minutes, while the effects of the opioids may last much longer. It is possible that after the naloxone wears off the overdose could recur. It is very important that someone stay with the person and wait out the risk period just in case another dose of naloxone is necessary. Also, naloxone can cause uncomfortable withdrawal feelings...
Jul 2nd, 2019 - Naloxone saves lives. But it must be available at the right time to someone who knows how to use it. Getting the opioid overdose antidote into the hands of first responders has been a lifesaver. But a person does not need to wear a uniform, white coat or scrubs to perform a rescue. In fact, nearly 80 percent of opioid-overdose deaths happen outside of a medical setting.
JAMA Network Open; Follman,S.,et al
May 2nd, 2019 - Question How often is naloxone prescribed in a clinical setting to US patients at high risk of opioid overdose? Findings In this cohort study using administrative data including 138 108 individuals, only 1.5% of high-risk patients, including individuals with prior opioid overdose or opioid misuse or dependence, were prescribed naloxone. Meaning Naloxone prescribing in ...
Aug 1st, 2017 - The nation’s opioid epidemic claimed more than 33,000 lives in 2015, but that figure would have been even higher if it wasn’t for the life-saving opioid overdose antidote naloxone. For more than 40 years, naloxone has been used to reverse the effects of opioid overdose. Timely administration of naloxone has saved thousands of lives:
Annals of Internal Medicine; Coffin PO, Behar E et. al.
Jul 1st, 2016 - Unintentional overdose involving opioid analgesics is a leading cause of injury-related death in the United States. To evaluate the feasibility and effect of implementing naloxone prescription to patients prescribed opioids for chronic pain. 2-year nonrandomized intervention study. 6 safety-net primary care clinics in San Francisco, California. 1985 adults receiving long-term opioid ther...
MMWR. Morbidity and Mortality Weekly Report; Budnitz DS, Lovegrove MC et. al.
Oct 20th, 2016 - Expanding access to office-based medication-assisted treatment with buprenorphine/naloxone for opioid dependence is a key part of the national strategy to address the opioid abuse epidemic (1). However, as buprenorphine/naloxone prescribing increased, emergency department (ED) visits and hospitalizations for unsupervised ingestions by young children began to increase, with bupreno...
Mar 4th, 2018 - Opioid use disorder is often a chronic, relapsing condition associated with increased morbidity and death, however, with appropriate treatment and follow-up, individuals can reach sustained long-term remission. This guideline strongly recommends opioid agonist treatment with buprenorphine–naloxone as the preferred first-line treatment when possible, because of buprenorphine’s multiple adv.
Dec 31st, 2010 - Buprenorphine/naloxone is an effective medication for the maintenance treatment of opioiddependence. It improves outcomes compared to detoxification and, with the exception ofretention in treatment, appears to be of equal efficacy compared to methadone.
Feb 24th, 2019 - In April 2018, NIH launched the HEAL (Helping to End Addiction Long-termSM) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. This Initiative will build on extensive, well-established NIH research, including basic science of the complex neurological pathways involved in pain and addiction, implementation science to dev...
Aug 1st, 2015 - The “Personal View” by Hall, Carter, and Forlini1 questions the value of the BDMA (brain disease model of addiction) and claims that it is not supported by animal or neuroimaging evidence, that it has not helped deliver more effective treatments and that its impact on public policy have been modest. However, these claims are not supported by the evidence. First, preclinical and clinical studies...